VRD方案治疗是一种针对多发性骨髓瘤(Multiple Myeloma,简称MM)的治疗方案。它是综合应用多种药物联合进行的治疗策略,能够有效控制疾病的进展,延长患者的生存期。VRD方案由小剂量地塞米松(Velcade)、利妥昔单抗(Revlimid)和地辛泼尼松(Dexamethasone)这三种药物组成。下面将详细介绍VRD方案治疗的原理、临床应用及其优点。
参考文献 DuMontier C, et al.More intensive therapy as more effective treatment for frail patients with multiple myeloma.Blood Adv . 2023 Aug 15;bloodadvances.2023011019. doi: 10.1182/bloodadvances.2023011019. 授权转载、投稿等请联络梅...
The IMROZstudy is a large phase three international trial that included centers in China and focused on newly diagnosed transplant-ineligible multiple myeloma patients. The primary goal was to assess the clinical value of adding isatuximab, an anti-CD38 monoclonal antibody, to the VRd regimen (bor...
3. Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma. News release. Sanofi. May 27, 2024. Accessed August 8, 2024. 4. Trial on the effect of isatuximab to l...
The phase 3 PERSEUS trial enrolled patients between 18 and 70 years of age with newly diagnosed multiple myeloma who were eligible for ASCT. An ECOG performance status of 0 to 2 was required.2 Patients were randomly assigned 1:1 to the D-VRd and VRd arms, where treatment was given in ...
on newly diagnosed transplant-ineligible multiple myeloma patients. The primary goal was to assess the clinical value of adding isatuximab, an anti-CD38 monoclonal antibody, to the VRd regimen (bortezomib, lenalidomide, and dexamethasone), which is a well-established treatment for multiple myeloma. ...
We identified 1354 patients who received ASCT as first-line treatment for multiple myeloma in Norway in the study period. Of these, 682 patients received VCD induction, 332 patients received VRD induction, and 42 patients received VTD induction. Baseline characteristics are described in Table1and we...
Bone marrow aspirate cytology of multiple myeloma: ©David A Litman - stock.adobe.com Treatment with subcutaneous daratumumab (Darzalex) followed by autologous stem cell transplant (ASCT), daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation...
The FDA received a sBLA that is seeking approval of D-VRd for the treatment of transplant-eligible patients with newly diagnosed multiple myeloma. Subcutaneous Daratumumab Plus VRd Seeks FDA Approval for Transplant-Eligible Multiple Myeloma A supplemental biologics license application (...
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for isatuximab combination treatment in the first article of a 2-part series. Andrzej Jakubowiak, MD, PhD Professor of Medicin...